Skip to main content

Research and decision-support for life sciences

The home for evidence-led research.

Veriomics brings literature intelligence and analytical workflow into one auditable platform. From your first search to the final report, every claim traces back to the evidence behind it.

The Veriomics closed loop: ten capabilities connected in dependency order, Lumen, Praxis, Veraxa, Nexora, Novora, Oris, Omnix, Sentinel, Prognos, with Labtrack feeding experimental outcomes back into Praxis.From researchto decision1Lumen2Praxis3Veraxa4Nexora5Novora6Oris7Omnix8Sentinel9Prognos10Labtrack
Closed-loop architecture diagram. The capabilities run in order: 1 Lumen, 2 Praxis, 3 Veraxa, 4 Nexora, 5 Novora, 6 Oris, 7 Omnix, 8 Sentinel, 9 Prognos, 10 Labtrack. Labtrack feeds experimental outcomes back into Praxis.

Backed by evidence

Every claim, suggestion, and value carries its citation inline - author, year, journal, and strength. Grounded in live literature, not model memory.

No false certainty

When the evidence isn't there, it says so, no fabricated values, no auto-executed clinical or policy actions.

Reproducible by design

Every report carries a reproducibility certificate, methods, parameters, versions, and seeds, fully recorded.

Built for the people who do the research, and the people who act on it

Across life sciences addressed as professionals, with the decision-support boundary explicit throughout.

Where research gets done

Every step connected, results loop straight back into the next design.

  • Consensus from full-text methods
  • Workflow execution with full provenance
  • Results loop back into the next design
  • Lab and analysis in one place
Explore the journey

Where clinical research lives

Hospital research arms and labs, built for the research the hospital runs.

  • Decision-support, evidence-ranked briefs
  • Every output marked research-only
  • Not for individual clinical diagnosis
  • Genomics and pathology research ready
Explore the journey

Surveillance to policy

Forecasting and policy briefs, built on public-health data that's usually locked away.

  • WHO GLASS and ECDC EARS-Net ingestion
  • Transparent harmonisation logic
  • Evidence-ranked options; the authority decides
  • Surveillance and outbreak forecasting
Explore the journey

Pharma, at scale

Regulated, multi-region R&D - governance and provenance across the whole platform.

  • Organisation workspaces and role governance
  • Multi-region data residency, no region privileged
  • Reproducibility certificates and full provenance
  • Audit-ready across the whole platform
Explore the journey

Structurally different, not cosmetically novel

Built into the architecture, not bolted onto a set of disconnected tools.

One evidential chainend to end
Consensus from real methodsnot abstracts
Research-only by constructionnot a bolted-on warning
Grounded in live literaturenot model memory
Surveillance data, unifiedFragmented public-health data, WHO GLASS, ECDC EARS-Net, national CDCs, harmonised into one analytical surface.
Reproducible by designEvery report ships with a reproducibility certificate, methods, parameters, software versions, and seeds, fully recorded.
Built into the architecture, not bolted on
Wet lab and dry labequal, one workflow
Active AI suggestioneverywhere
Universally accessiblearchitecture

One architecture, end to end

Each one feeds the next. Open any capability to see how its outputs are grounded.

Surveillance intelligence

From fragmented surveillance to a forecast you can interrogate.

See where resistance is heading, not just where it’s been, forecasts built on live surveillance data, with alerts when trajectories shift.

Ciprofloxacin resistance trajectory, E. coli
Illustrative forecast of E. coli resistance to ciprofloxacin rising from 20 percent in 2018 to 35 percent in 2024, projected to about 41 percent by 2027 with a widening confidence interval.10%20%30%40%50%201820202022202420262027forecast →
Observed Projected Confidence interval

See whether the closed loop fits your research

One email, one form. Tell us about your work and the tier you fall into, and we will follow up.